Ambit Biosciences

About:

Ambit Biosciences, a biopharmaceutical company, develops small molecule kinase inhibitors for cancer and inflammatory disease treatments.

Website: http://www.ambitbio.com

Top Investors: OrbiMed, Horizon Technology Finance, Avalon Ventures, Forward Ventures, Aisling Capital

Description:

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Total Funding Amount:

$216M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

San Diego, California, United States

Founded Date:

2000-01-01

Contact Email:

sales(AT)ambitbio.com

Founders:

Kevin Kinsella

Number of Employees:

51-100

Last Funding Date:

2012-11-06

IPO Status:

Delisted

Industries:

© 2025 bioDAO.ai